Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.39 |
| ▸ | SLCO1B3 | Q9NPD5 | 6/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | SULT1E1 | P49888 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fraxinellone SCHEMBL17503654 | 1.00 | GAA (1.00) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| Fraxinellone SCHEMBL25272092 | 1.00 | GAA (1.00) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| SCHEMBL30008897 | 0.84 | GAA (0.72) | GAATSHRSULT1E1ALDH1A1 | |
| Fraxinellonone SCHEMBL29065291 | 0.82 | GAA (0.70) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| 4Alpha-Hydroxyfraxinellone SCHEMBL30697308 | 0.80 | GAA (0.66) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| 4Alpha-Hydroxyfraxinellone SCHEMBL30150287 | 0.80 | GAA (0.66) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| SCHEMBL30150288 | 0.79 | GAA (0.65) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| SCHEMBL30574475 | 0.62 | GAA (0.46) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| SCHEMBL19590566 | 0.62 | GAA (0.45) | GAATSHRCYP3A4SLCO1B3SLCO1B1 | |
| SCHEMBL30150305 | 0.61 | GAA (0.44) | GAATSHRCYP3A4SLCO1B3SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023117768-A1 | COMBINATION OF DRUGS FOR THE TREATMENT OF CANCER | SCANDION ONCOLOGY A/S (DK) | 2023-06-29 | — | — | WO | claimed |
| EP-4197525-A1 | COMBINATION OF DRUGS FOR THE TREATMENT OF CANCER | Scandion Oncology A/S (DK) | 2023-06-21 | — | — | EP | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4691496-A1 | PHARMACEUTICAL PREPARATION CONTAINING GLP-1 FUSION PROTEIN AND USE THEREOF | Guangzhou Innogen Pharmaceutical Group Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250376498-A1 | FUSION PROTEINS COMPRISING AN IMPROVED GLP-1 RECEPTOR AGONIST AND USES THEREOF | GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO LTD (CN) | 2025-12-11 | — | — | US | disclosed |
| EP-3995586-B1 | GLYCOSYLATED PROTEIN ASSAY REAGENT CONTAINING PROTEASE STABILIZER INCREASING REDOX POTENTIAL OF FERROCYANIDE, METHOD FOR ASSAYING GLYCOSYLATED PROTEIN, METHOD FOR PRESERVING GLYCOSYLATED PROTEIN ASSAY REAGENT, AND METHOD FOR STABILIZING GLYCOSYLATED PROTEIN ASSAY REAGENT | NAGASE DIAGNOSTICS CO LTD (JP) | 2025-11-05 | — | — | EP | disclosed |
| CN-114267421-B | Extraction process for optimizing three effective components of cortex dictamni by combining analytic hierarchy process with response surface method | 吉林化工学院 | 2025-05-23 | — | — | CN | disclosed |
| EP-4545570-A1 | FUSION PROTEIN CONTAINING IMPROVED GLP-1 RECEPTOR AGONIST AND USES | Guangzhou Innogen Pharmaceutical Group Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20240238295-A1 | METHOD FOR MODULATING NEUROPATHIES | CHENGDU WENDING TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240178398-A1 | WATER BASED BINDER COMPOSITION AND APPLICATION THEREOF | ARKEMA INC. | 2024-05-30 | — | — | US | disclosed |
| EP-2976457-B1 | TEXTILE PRODUCTS WITH HERBAL COMPOSITION TO RENDER THE FABRICS INSECTS REPELLENT | SYNTIS TEXTILE PRIVATE LTD (IN) | 2019-08-07 | — | — | EP | disclosed |
| US-9816227-B2 | Textile products with herbal composition to render the fabrics insects repellent | SYNTIS TEXTILE PRIVATE LTD (IN) | 2017-11-14 | — | — | US | disclosed |
| US-9816227-B2 | Textile products with herbal composition to render the fabrics insects repellent | SYNTIS TEXTILE PRIVATE LTD (IN) | 2017-11-14 | — | — | US | disclosed |
| US-9816227-B2 | Textile products with herbal composition to render the fabrics insects repellent | SYNTIS TEXTILE PRIVATE LTD (IN) | 2017-11-14 | — | — | US | disclosed |
| US-20160047086-A1 | TEXTILE PRODUCTS WITH HERBAL COMPOSITION TO RENDER THE FABRICS INSECTS REPELLENT | SYNTIS TEXTILE PRIVATE LTD (IN) | 2016-02-18 | — | — | US | disclosed |
| US-20160047086-A1 | TEXTILE PRODUCTS WITH HERBAL COMPOSITION TO RENDER THE FABRICS INSECTS REPELLENT | SYNTIS TEXTILE PRIVATE LTD (IN) | 2016-02-18 | — | — | US | disclosed |
| US-20160047086-A1 | TEXTILE PRODUCTS WITH HERBAL COMPOSITION TO RENDER THE FABRICS INSECTS REPELLENT | SYNTIS TEXTILE PRIVATE LTD (IN) | 2016-02-18 | — | — | US | disclosed |
| CN-101618106-B | Pharmaceutical composition for curing psoriasis | JILIN CAOHUANDAN PHARMACEUTICAL CO LTD | 2012-02-29 | — | — | CN | disclosed |
| CN-101618106-A | Pharmaceutical composition for curing psoriasis | JILIN CAOHUANDAN PHARMACEUTICA | 2010-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376498-A1 | FUSION PROTEINS COMPRISING AN IMPROVED GLP-1 RECEPTOR AGONIST AND USES THEREOF | GLP1R, GIPR, GCGR | GAA 864/4885TSHR 166/4885CYP3A4 4606/4885 |
| US-20160047086-A1 | TEXTILE PRODUCTS WITH HERBAL COMPOSITION TO RENDER THE FABRICS INSECTS REPELLENT | CRY1, TREH, TMSB10 | GAA 2280/4885TSHR 1790/4885CYP3A4 583/4885 |
| US-20240238295-A1 | METHOD FOR MODULATING NEUROPATHIES | MME, PMP22, NEFM | GAA 1205/4885TSHR 2533/4885CYP3A4 1596/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | GAA 1518/4885TSHR 4804/4885CYP3A4 3867/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | GAA 931/4885TSHR 4819/4885CYP3A4 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.